Stock Ratings / Health Care / PHIO / earnings

BLRX (60) GDTC (54) TPST (44) BFRG (40) ⌘ Pro Terminal →

Phio Pharmaceuticals Corp. (PHIO) Next Earnings Date & Expected ±12.5% Move

$0.86 -5.91% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.85

Phio Pharmaceuticals Corp. (PHIO) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $10.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.85 (-1.25%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PHIO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY PHIO SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$0.98-11.2% Next Q

Q2 (-2Q)

Grade D$0.87-2.3% Next Q

Q3 (-1Q)

Grade D$0.85+1.2% Next Q

Current

Grade D-$0.86-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PHIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PHIO currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.00) and Max Pain ($0.90) forces dealer call-delta covering toward $4.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PHIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PHIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.11 Expected Swing

MODEL EARNINGS SETUP GAUGE

PHIO Quantitative Pre-Earnings Setup: 42/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (42/100)Model Risk Weight (58/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$8.7M	-$8.0M	52%
FY 2024	2024-12-31	$0	-$7.2M	-$7.1M	52%
FY 2023	2023-12-31	$0	-$10.8M	-$10.7M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PHIO)

✓Walkthrough of PHIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PHIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.51%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.86H $0.88L $0.85C $0.86VOL 66.7K

RES: $1.32SUP: $0.83SMA50: $1.00SMA200: $1.09

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PHIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PHIO Butterfly Map → + Track PHIO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PHIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PHIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PHIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PHIO)

Health Care Rank #594 of 1016 ⚔️ BLRX vs PHIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PHIO vs. BLRX, GDTC, TPST, BFRG)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Phio Pharmaceuticals Corp. (PHIO) ranks #594 by composite RQD confidence (42/100, grade D-) and #896 by equity capitalization ($10.0M). Within this direct 5-issuer industry benchmark cohort, PHIO leads on earnings valuation at N/A trailing P/E, while PHIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with PHIO at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PHIO ACTIVE Phio Pharmaceuticals Corp.	D-	42/100	—	—	-35.0%	-5.91%	$10.0M	Benchmark Subject
BLRX BioLineRx Ltd.	C-	60/100	—	—	—	+1.00%	$10.1M	/blrx-vs-phio →
GDTC CytoMed Therapeutics Limited	D+	54/100	—	—	—	-3.68%	$10.7M	/gdtc-vs-phio →
TPST Tempest Therapeutics Inc.	D	44/100	—	—	-35.0%	-1.24%	$10.7M	/tpst-vs-phio →
BFRG Bullfrog AI Holdings Inc.	D-	40/100	—	18.8%	-35.0%	+3.88%	$9.4M	/bfrg-vs-phio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001533040

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Phio Pharmaceuticals Corp. (PHIO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.7M, operating cash flow of -$8.0M, and free cash flow of -$8.0M (-12.3% YoY). On the balance sheet, PHIO closed FY2025 with $21.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$8.7M	-$8.0M	-$8.0M	$21.5M	—
FY2024 (FY)	2024-12-31	$0	-$7.2M	-$7.1M	-$7.1M	$5.7M	—
FY2023 (FY)	2023-12-31	$0	-$10.8M	-$10.7M	-$10.7M	—	—

3. PHIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PHIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.86 (-5.91% 1D, market cap $10.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PHIO ranks #594 in composite RQD confidence.

How does PHIO compare to BLRX and GDTC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHIO carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BLRX (BioLineRx Ltd.) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $10.1M) and GDTC (CytoMed Therapeutics Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $10.7M). Among the 5-stock peer group, PHIO leads on earnings multiple (N/A) while PHIO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PHIO?

Per PHIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533040), Phio Pharmaceuticals Corp. generated $0 in revenue, -$8.7M in net income, and -$8.0M in free cash flow against $21.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PHIO trading relative to its 50-day, 200-day, and 52-week technical levels?

PHIO last traded at $0.86 (-5.91% on volume of 26,721 shares), positioning the stock -14.00% below its 50-day simple moving average ($1.00) and -21.10% below its 200-day simple moving average ($1.09). Across its 52-week range of $0.81 to $4.19, PHIO sits at the 1.5% percentile with a 14-day RSI of 37.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.97).